IDM Pharma, Inc. (IDMI) Updates Shareholders on Cancer Clinical Trial
IDM Pharma, Inc. (IDMI) updated shareholders on results from the Phase 2 UVIDEM® (IDD-3) melanoma vaccine clinical trial (DC-MEL-202). These updated clinical trial results have shown that the investigational agent "UVIDEM" induction into human immune systems was well tolerated with patients suffering advanced melanoma. The data was presented during a poster session at the International Society for Biological Therapy of Cancer (iSBTc) annual meeting today in Boston. "There is a distinct need in the medical community for new treatments for metastatic melanoma," said Dr. Antoni Ribas, associate professor of medicine and surgery at UCLA and associate director of tumor immunology at…